AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed diagnosis of 1 of the following:

  * Advanced and/or metastatic solid tumor

    * No more than 3 prior regimens for metastatic disease
  * Refractory non-Hodgkin's lymphoma
* Clinically or radiologically documented disease

  * Patients whose only evidence of disease is tumor marker elevation are not eligible
* No untreated brain or meningeal metastases

  * Patients with radiologic or clinical evidence of stable, treated brain metastases are eligible provided they are asymptomatic AND have no requirement for corticosteroids

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Absolute granulocyte count ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Creatinine ≤ 1.25 times upper limit of normal (ULN) OR creatinine clearance ≥ 50 mL/min
* Bilirubin normal
* ALT and AST ≤ 2 times ULN (5 times ULN if patient has documented liver metastases)
* Potassium normal
* Calcium normal
* Creatine kinase (CK or CPK) ≤ 2 times ULN
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No pre-existing cardiovascular conditions and/or symptomatic cardiac dysfunction, including any of the following:

  * Significant cardiac event (including symptomatic heart failure or angina) within the past 3 months or any cardiac disease that, in the opinion of the investigator, increases the risk for ventricular arrhythmia
  * Any history of ventricular arrhythmia, which was symptomatic or required treatment (CTC grade 3), including multifocal PVCs, bigeminy, trigeminy, or ventricular tachycardia
  * Uncontrolled hypertension
  * Previous history of QT prolongation with other medication
  * Congenital long QT syndrome
  * QT and QTc, with Bazett's correction, unmeasurable or ≥ 460 msec on screening ECG
  * LVEF \< 45 % by MUGA for patients with significant cardiac history (i.e., myocardial infarction, severe hypertension, or arrhythmia) or prior doxorubicin (\> 450 mg/m²)
* No active or uncontrolled infections
* No serious illness or medical condition that would preclude study compliance
* No peripheral neuropathy \> grade 1

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* At least 21 days since prior cytotoxic chemotherapy and recovered (solid tumors)
* At least 21 days since prior palliative radiotherapy and recovered

  * Exceptions may be made for low-dose, nonmyelosuppressive radiotherapy
* Prior hormonal, immunologic, biologic, or signal transduction inhibitor therapy allowed
* At least 14 days since prior major surgery and recovered (no nonhealing wounds)
* At least 4 weeks since prior steroids
* No other concurrent medications which affect QT/QTc and cannot be discontinued
* No other concurrent experimental drugs or anticancer therapy